SciClone Pharmaceuticals Stock Downgraded (SCLN)

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

NEW YORK ( TheStreet) -- SciClone Pharmaceuticals (Nasdaq: SCLN) has been downgraded by TheStreet Ratings from buy to hold. The company's strengths can be seen in multiple areas, such as its expanding profit margins and increase in stock price during the past year. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, disappointing return on equity and feeble growth in the company's earnings per share.

  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

Highlights from the ratings report include:
  • The gross profit margin for SCICLONE PHARMACEUTICALS INC is currently very high, coming in at 89.06%. It has increased from the same quarter the previous year. Regardless of the strong results of the gross profit margin, the net profit margin of -6.76% is in-line with the industry average.
  • Compared to where it was 12 months ago, the stock is up, but it has so far lagged the appreciation in the S&P 500. Despite the fact that it has already risen in the past year, there is currently no conclusive evidence that warrants the purchase or sale of this stock.
  • The revenue fell significantly faster than the industry average of 2.5%. Since the same quarter one year prior, revenues fell by 29.2%. Weakness in the company's revenue seems to have hurt the bottom line, decreasing earnings per share.
  • The company, on the basis of change in net income from the same quarter one year ago, has significantly underperformed when compared to that of the S&P 500 and the Pharmaceuticals industry. The net income has significantly decreased by 117.7% when compared to the same quarter one year ago, falling from $11.23 million to -$1.98 million.
  • Return on equity has greatly decreased when compared to its ROE from the same quarter one year prior. This is a signal of major weakness within the corporation. Compared to other companies in the Pharmaceuticals industry and the overall market, SCICLONE PHARMACEUTICALS INC's return on equity significantly trails that of both the industry average and the S&P 500.

SciClone Pharmaceuticals, Inc. provides therapies for the treatment of oncology, infectious diseases, cardiovascular, urological, respiratory, and central nervous system disorders in the People's Republic of China and internationally. SciClone has a market cap of $321.8 million and is part of the health care sector and drugs industry. Shares are up 38.1% year to date as of the close of trading on Friday.

You can view the full SciClone Ratings Report or get investment ideas from our investment research center.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more..
Disclosure: TheStreet's editorial policy prohibits staff editors, reporters and analysts from holding positions in any individual stocks.

If you liked this article you might like

Drug Price Inflation and a Patent Cliff Could Trigger a Wave of Deals in Generic Drugs Space

Merck Up on Approval, Teva Sinks on Earnings and Asset Sales: Biotech Movers

Today's Weak On High Volume Stock: SciClone Pharmaceuticals (SCLN)

SciClone Pharmaceuticals (SCLN): Today's Weak On High Volume Stock

Jim Cramer's 'Mad Money' Recap: Here's This Week's Game Plan